Navigation Links
BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
Date:7/29/2008

oing surgery. Rocuronium was administered at a standard dose to allow intubation, followed by maintenance doses as required. When 1-2 post-tetanic counts (PTC) were observed following neuromuscular stimulation (deep block), patients were administered either sugammadex or neostigmine plus glycopyrrolate, a current reversal regimen. In the SIGNAL trial, the median time to reversal of muscle relaxation to a train-of-four (TOF) ratio of 0.9 occurred in 2.7 minutes in the sugammadex group compared to 49.0 minutes in the neostigmine/glycopyrrolate group.

The AURORA trial involved adult patients undergoing surgery. Rocuronium was administered at a standard dose to allow intubation, followed by maintenance doses as required. At the reappearance of the second twitch (T2) in a TOF stimulation (moderate block) patients were administered either sugammadex or neostigmine plus glycopyrrolate. In the AURORA trial, the median time to reversal of muscle relaxation to a TOF ratio of 0.9 occurred in 1.4 minutes in the sugammadex group compared to 17.6 minutes in the neostigmine/glycopyrrolate group.

The SPECTRUM trial was conducted in adult patients undergoing surgery to study the immediate reversal of muscle relaxation. Patients were randomized to receive either rocuronium plus sugammadex or the rapid-onset, short- duration muscle relaxant succinylcholine. The trial demonstrated that rocuronium followed by sugammadex is an effective alternative to succinylcholine.

The EC approval of BRIDION follows a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) that was received in May of this year.

About BRIDION (sugammadex)

BRIDION, the first and only selective relaxant binding agent (SRBA), is the first major pharmaceutical advance in the field of anesthesia in two decades. It was specifically designed to rapidly reverse both moderate and deep muscle relaxation induced by the commonly used m
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
2. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
3. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
4. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
7. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
8. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
9. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
10. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
11. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014  CytRx Corporation (Nasdaq: CYTR ), ... today announced that David J. Haen , Vice ... in the Biotech Industry Conference on Friday, September 26 th ... take place at the Millennium Broadway Hotel in ... live and archived webcast of the presentation will be ...
(Date:9/19/2014)... PHILADELPHIA , Sept. 19, 2014  PCI ... Services International (Biotec).  Biotec is a leading provider ... Services headquartered in Bridgend, Wales ... .  The addition significantly expands PCI,s presence in ... medicinal products by adding packaging, storage and distribution ...
(Date:9/18/2014)... Sept. 18, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... focused on licensing, developing and commercializing innovative biopharmaceutical ... exercise of the underwriters, option to purchase 675,000 ... the company,s previously announced public offering of 4,500,000 ... are being offered by Aratana Therapeutics.  With the ...
Breaking Medicine Technology:CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2
... U.S. Food and Drug Administration (FDA) approved ... of INTELENCE ® (etravirine), a non-nucleoside reverse transcriptase ... virus (HIV-1) in treatment-experienced adults with resistance to an ... The recommended oral dose of INTELENCE tablets is 200 ...
... KONG, Jan. 3, 2011 /PRNewswire-Asia-FirstCall/ -- Golden Meditech ... with its subsidiary collectively as the "Group" - 801.HK), ... announce that the Company has obtained the approvals from ... Futures Bureau for its proposed offering and listing of ...
Cached Medicine Technology:FDA Approves New Dosage Strength for INTELENCE® 2FDA Approves New Dosage Strength for INTELENCE® 3FDA Approves New Dosage Strength for INTELENCE® 4FDA Approves New Dosage Strength for INTELENCE® 5Golden Meditech as First Chinese Healthcare Enterprise to Obtain Approval for Taiwan Depositary Receipts Offering 2
(Date:9/19/2014)... September 19, 2014 The Alliance ... partnership with the National Fire Protection Association (NFPA), ... collaboration, formalized today in a Memorandum of Understanding ... factories, workers and other stakeholders with information, guidance ... protect the health and safety of workers in ...
(Date:9/19/2014)... 2014 "I have difficulty putting in ... to stretching the skin around my eyes during the ... me to design a more convenient method of performing ... provides a quicker, easier, more sanitary method of putting ... this task manually, saves time and effort, and helps ...
(Date:9/19/2014)... approaches to reducing poverty that help children and ... advocates, and foundations. By combining education and training ... jobs that offer a path out of poverty ... these programs aim to improve the life opportunities ... report from the National Center for Children in ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- When it comes ... in the United States, while the District of Columbia ... the past decade, deaths from gun-related violence -- including ... the United States, the study revealed. Hawaii,s rate was ... of the spectrum, the District of Columbia had the ...
(Date:9/19/2014)... collaborative research team led by Medical College of Wisconsin (MCW) ... and insulin levels in rats, mice and in humans. The ... Genetics . , Leah Solberg Woods, Ph.D., associate ... Children,s Hospital of Wisconsin Research Institute, led the study and ... of the paper identified a gene called Tpcn2 in which ...
Breaking Medicine News(10 mins):Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3Health News:A two generation lens: Current state policies fail to support families with young children 2Health News:U.S. Gun Deaths Lowest in Hawaii, Highest in D.C. 2
... Dietary Guidelines (i.e., men who usually drink more than two ... one drink per day) or those who binge drink are ... new study accepted for publication in The Endocrine Society,s ... metabolic syndrome consists of a series of risk factors and ...
... Shows Overuse of Technology Is Wreaking ... Havoc on Romance -, ... juggling lengthy to-do lists, jam-packed schedules, and the 24/7,demands of children and ... wired lifestyle allows people to stay,connected with more friends, family and co-workers ...
... following news tips are based on poster and oral presentations ... in Chicago from July 26 to July 31. Each presentation ... Brain Atrophy and Biomarkers May Help Identify People at Risk ... Department of Psychiatry, NYU Langone Medical Center , EMBARGOED FOR ...
... VNUS(R) Medical,Technologies, Inc. (Nasdaq: VNUS ) updates and corrects ... 2008 net income is expected to,range from approximately $13.1 million ... which is changed from the previously announced net,income of $11.5 ... per,share., ABOUT VNUS MEDICAL TECHNOLOGIES, INC., VNUS is ...
... and Charitable Care and Coverage, OAKLAND, Calif., ... has approved more than 415 community benefit grants ... quarter of 2008.,The quarter,s contributions continue to support ... measurable impact on the health of,its communities., ...
... PORTLAND, Ore., July 29 Sometimes the simplest ... to health care --,are the most difficult., Regence ... company has launched a Web site that enables consumers ... health-related topics., The video cards are part of ...
Cached Medicine News:Health News:Drinking in excess associated with increased risk for metabolic syndrome 2Health News:Gold Medalist Jennie Finch & Relationship Expert Stacy Kaiser Help 'Wired' Couples Unplug 2Health News:Gold Medalist Jennie Finch & Relationship Expert Stacy Kaiser Help 'Wired' Couples Unplug 3Health News:Gold Medalist Jennie Finch & Relationship Expert Stacy Kaiser Help 'Wired' Couples Unplug 4Health News:New Alzheimer's predictors advance earlier detection 2Health News:New Alzheimer's predictors advance earlier detection 3Health News:New Alzheimer's predictors advance earlier detection 4Health News:New Alzheimer's predictors advance earlier detection 5Health News:New Alzheimer's predictors advance earlier detection 6Health News:New Alzheimer's predictors advance earlier detection 7Health News:New Alzheimer's predictors advance earlier detection 8Health News:VNUS Revises Upward Full-Year 2008 Net Income Guidance 2Health News:Kaiser Permanente Approves $22 Million in Community Benefit Grants in Second Quarter of 2008 2Health News:Kaiser Permanente Approves $22 Million in Community Benefit Grants in Second Quarter of 2008 3Health News:Regence Video Cards Help Start Important Health Conversations With Friends, Family 2
... was the first device ... after diagnostic and interventional ... It is a collagen-based ... for immediate sheath removal ...
... VasoSeal VHD was ... rapidly stop bleeding after ... and radiology procedures. It ... sealing device approved for ...
InterVascular HemaPatch product line offers the vascular surgeon a range of collagen coated patches in a range of larger sizes angioplasty, or profundaplasty procedures without suture hole bleeding. ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
Medicine Products: